CA2277273C - Antagonistes d'integrine - Google Patents
Antagonistes d'integrine Download PDFInfo
- Publication number
- CA2277273C CA2277273C CA002277273A CA2277273A CA2277273C CA 2277273 C CA2277273 C CA 2277273C CA 002277273 A CA002277273 A CA 002277273A CA 2277273 A CA2277273 A CA 2277273A CA 2277273 C CA2277273 C CA 2277273C
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutically acceptable
- compound
- alkyl
- inhibition
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
L'invention concerne certains nouveaux composés et leurs derivés, leur synthèse et leur utilisation comme antagonistes de récepteur vitronectine. Les composés antagonistes de récepteur de vitronectine décrits sont des antagonistes alpha v beta 3, des antagonistes alpha v beta 5 ou des antagonistes doubles alpha v beta 3/ alpha v beta 5, utiles pour inhiber la résorption osseuse, traiter et prévenir l'ostéoporose et inhiber la resténose, la rétinopathie diabétique, la dégénérescence maculaire, l'angiogénèse, l'athérosclérose, l'inflammation, les maladies virales et la croissance tumorale.
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3561497P | 1997-01-17 | 1997-01-17 | |
US60/035,614 | 1997-01-17 | ||
GBGB9702788.2A GB9702788D0 (en) | 1997-02-11 | 1997-02-11 | Alpha v beta 3 antagonists |
US6259497P | 1997-10-20 | 1997-10-20 | |
US60/062,594 | 1997-10-20 | ||
GB9702788.2 | 1997-12-09 | ||
GBGB9725996.4A GB9725996D0 (en) | 1997-12-09 | 1997-12-09 | Intergrin antagonists |
GB9725996.4 | 1997-12-09 | ||
PCT/US1998/000617 WO1998031359A1 (fr) | 1997-01-17 | 1998-01-13 | Antagonistes d'integrine |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2277273A1 CA2277273A1 (fr) | 1998-07-23 |
CA2277273C true CA2277273C (fr) | 2008-03-25 |
Family
ID=27451601
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002277273A Expired - Fee Related CA2277273C (fr) | 1997-01-17 | 1998-01-13 | Antagonistes d'integrine |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1007026A4 (fr) |
JP (1) | JP2001509176A (fr) |
AU (1) | AU729869B2 (fr) |
CA (1) | CA2277273C (fr) |
WO (1) | WO1998031359A1 (fr) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19629816A1 (de) | 1996-07-24 | 1998-01-29 | Hoechst Ag | Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten |
US6066648A (en) | 1997-12-17 | 2000-05-23 | Merck & Co., Inc. | Integrin receptor antagonists |
US6048861A (en) * | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
US6211191B1 (en) | 1997-12-17 | 2001-04-03 | Merck & Co., Inc. | Integrin receptor antagonists |
US6017926A (en) * | 1997-12-17 | 2000-01-25 | Merck & Co., Inc. | Integrin receptor antagonists |
US6313119B1 (en) | 1998-01-23 | 2001-11-06 | Adventis Pharma Deutschland Gmbh | Sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion |
US6372719B1 (en) * | 1998-03-04 | 2002-04-16 | Jay Cunningham | ανβ3 integrin antagonists in combination with chemotherapeutic agents |
GB9805655D0 (en) | 1998-03-16 | 1998-05-13 | Celltech Therapeutics Ltd | Chemical compounds |
US6521626B1 (en) | 1998-03-24 | 2003-02-18 | Celltech R&D Limited | Thiocarboxamide derivatives |
GB9814414D0 (en) | 1998-07-03 | 1998-09-02 | Celltech Therapeutics Ltd | Chemical compounds |
US7008645B2 (en) | 1998-07-14 | 2006-03-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Method of inhibiting restenosis using bisphosphonates |
IL125336A0 (en) * | 1998-07-14 | 1999-03-12 | Yissum Res Dev Co | Compositions for inhibition and treatment of restinosis |
US6984400B2 (en) | 1998-07-14 | 2006-01-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Method of treating restenosis using bisphosphonate nanoparticles |
WO2000006169A1 (fr) * | 1998-07-29 | 2000-02-10 | Merck & Co., Inc. | Antagonistes des recepteurs de l'integrine |
DE19842415A1 (de) * | 1998-09-16 | 2000-03-23 | Merck Patent Gmbh | Pharmazeutische Zubereitung |
GB9821061D0 (en) | 1998-09-28 | 1998-11-18 | Celltech Therapeutics Ltd | Chemical compounds |
GB9826174D0 (en) | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
CN1398189A (zh) * | 1998-12-23 | 2003-02-19 | G.D.西尔公司 | 用于治疗肿瘤形成的放疗与cox-2抑制剂的联合治疗 |
BR0009593A (pt) | 1999-04-06 | 2002-06-18 | Sankyo Co | Agente melhorador de resistência à insulina, agente hipoglicêmico, agente imunorregulador, inibidor de aldose redutase, inibidor de 5-lipoxigenase, supressor de produção de lipìdios peroxidados, ativador de ppar, antagonista de leucotrienos, promotor de formação hidroxiadipocelular ou antagonista de cálcio, agente preventivo e/ou terapêutico, derivados de ácido carboxìlico, medicamento, composição farmacêutica, e, uso de um composto |
GB9908355D0 (en) * | 1999-04-12 | 1999-06-09 | Rhone Poulenc Rorer Ltd | Chemical compounds |
GB9910394D0 (en) * | 1999-05-05 | 1999-07-07 | Rhone Poulenc Rorer Ltd | Chemical compounds |
US6518283B1 (en) | 1999-05-28 | 2003-02-11 | Celltech R&D Limited | Squaric acid derivatives |
BR0011108A (pt) | 1999-06-02 | 2002-03-19 | Merck & Co Inc | Composto, composição farmacêutica, e, processos de eliciar um efeito antagonizante do receptor da integrina, de tratamento ou prevenção da osteoporose, de tratamento ou prevenção de uma condição mediada por antagonismo de um receptor de integrina, de inibição da reabsorção óssea em um mamìfero em necessidade do mesmo, e de tratamento do desenvolvimento tumoral |
WO2000075129A1 (fr) * | 1999-06-07 | 2000-12-14 | Shire Biochem Inc. | Inhibiteurs d'integrine thiophene |
EP1065207A1 (fr) | 1999-07-02 | 2001-01-03 | Aventis Pharma Deutschland GmbH | Dérivées de la naphthyridine, procédés pour leur preparation, leur utilisation, et compositions pharmaceutique les contenant |
EP1065208A1 (fr) * | 1999-07-02 | 2001-01-03 | Aventis Pharma Deutschland GmbH | Dérivés substitués de la purine inhibiteurs de l'adhésion cellulaire |
WO2001007036A1 (fr) * | 1999-07-21 | 2001-02-01 | American Home Products Corporation | Antagonistes bicycliques selectifs contre l'integrine $g(a)v$g(b)¿3? |
EP1209152A4 (fr) | 1999-08-05 | 2003-03-12 | Meiji Seika Kaisha | Derives d'acide omega-amino-alpha-hydroxycarboxylique possedant un antagonisme alpha v beta 3 d'integrine |
US6534513B1 (en) | 1999-09-29 | 2003-03-18 | Celltech R&D Limited | Phenylalkanoic acid derivatives |
US6455539B2 (en) | 1999-12-23 | 2002-09-24 | Celltech R&D Limited | Squaric acid derivates |
ATE375330T1 (de) | 2000-04-17 | 2007-10-15 | Ucb Pharma Sa | Enamin-derivate als zell-adhäsionsmoleküle |
US6545013B2 (en) | 2000-05-30 | 2003-04-08 | Celltech R&D Limited | 2,7-naphthyridine derivatives |
US6403608B1 (en) | 2000-05-30 | 2002-06-11 | Celltech R&D, Ltd. | 3-Substituted isoquinolin-1-yl derivatives |
EP1289959A1 (fr) | 2000-06-15 | 2003-03-12 | Pharmacia Corporation | Derives d'acide alkanoique dihydrostilbene utilises comme antagonistes de la vitronectine |
UY26780A1 (es) | 2000-06-15 | 2002-01-31 | Pharmacia Corp | Cicloalquil avb3 antagonistas |
EP1296949A2 (fr) | 2000-06-21 | 2003-04-02 | Bristol-Myers Squibb Pharma Company | Amides de piperidine utilises comme modulateurs de l'activite des recepteurs des chimiokines |
EP1301488A1 (fr) | 2000-07-07 | 2003-04-16 | Celltech R&D Limited | Derives d'acide squarique contenant un noyau heteroaromatique bicyclique comme antagonistes d'integrine |
WO2002010136A1 (fr) | 2000-08-02 | 2002-02-07 | Celltech R & D Limited | Derives d'isoquinoline-1-yl substitues en 3 |
US6531494B1 (en) | 2001-08-29 | 2003-03-11 | Pharmacia Corporation | Gem-substituted αvβ3 antagonists |
ATE510557T1 (de) | 2001-04-24 | 2011-06-15 | Merck Patent Gmbh | Kombinationstherapie mit antiangiogenen mitteln und tnfalpha |
EA006860B1 (ru) | 2002-01-29 | 2006-04-28 | Уайт | Композиции и способы модулирования гемиканалов коннексина |
US7365209B2 (en) | 2003-02-11 | 2008-04-29 | Pharmacopeia, Inc. | Nitrogen heterocycle biaryls for osteoporosis and other diseases |
US10517883B2 (en) | 2003-06-27 | 2019-12-31 | Zuli Holdings Ltd. | Method of treating acute myocardial infarction |
JP2007505939A (ja) * | 2003-09-23 | 2007-03-15 | ノバルティス アクチエンゲゼルシャフト | Vegf受容体阻害剤と他の治療剤の組み合わせ |
WO2007084670A2 (fr) | 2006-01-18 | 2007-07-26 | Merck Patent Gmbh | Traitement specifique utilisant des ligands de l’integrine destine a traiter un cancer |
AU2007235577B2 (en) | 2006-03-31 | 2011-09-15 | Janssen Pharmaceutica N.V. | Benzoimidazol-2-yl pyridines as modulators of the histamine H4 receptor |
EA016264B1 (ru) | 2006-03-31 | 2012-03-30 | Янссен Фармацевтика Н.В. | Бензоимидазол-2-илпиримидины и пиразины в качестве модуляторов рецептора гистамина н |
ES2399159T3 (es) | 2007-01-18 | 2013-03-26 | Merck Patent Gmbh | Terapia y medicamento específicos usando ligandos de integrinas para el tratamiento del cáncer |
US8084466B2 (en) | 2007-12-18 | 2011-12-27 | Janssen Pharmaceutica Nv | Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor |
US9371311B2 (en) | 2008-06-30 | 2016-06-21 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyrimidine derivatives |
CA2763275A1 (fr) | 2009-05-25 | 2010-12-02 | Merck Patent Gmbh | Administration continue de ligands d'integrines pour le traitement du cancer |
PL2964229T3 (pl) | 2013-03-06 | 2020-05-18 | Janssen Pharmaceutica Nv | Benzoimidazol-2-ilo pirymidynowe modulatory receptora histaminowego H<sub>4</sub> |
US9993427B2 (en) | 2013-03-14 | 2018-06-12 | Biorest Ltd. | Liposome formulation and manufacture |
PL3050878T3 (pl) | 2013-09-24 | 2022-01-24 | Fujifilm Corporation | Zawierający atom azotu związek lub jego sól, lub ich kompleks z metalem |
MX2016015467A (es) | 2014-05-30 | 2017-03-23 | Pfizer | Derivados de carbonitrilo como moduladores selectivos del receptor de androgenos. |
CN109996541A (zh) | 2016-09-07 | 2019-07-09 | 普利安特治疗公司 | N-酰基氨基酸化合物及其使用方法 |
US12036286B2 (en) | 2021-03-18 | 2024-07-16 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
WO2023275715A1 (fr) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Métabolites de modulateurs sélectifs du récepteur des androgènes |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU675689B2 (en) * | 1992-12-01 | 1997-02-13 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
US5563158A (en) * | 1993-12-28 | 1996-10-08 | The Dupont Merck Pharmaceutical Company | Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists |
JPH10501222A (ja) * | 1994-05-27 | 1998-02-03 | メルク エンド カンパニー インコーポレーテッド | 破骨細胞仲介骨吸収を抑制するための化合物 |
-
1998
- 1998-01-13 WO PCT/US1998/000617 patent/WO1998031359A1/fr not_active Application Discontinuation
- 1998-01-13 EP EP98903466A patent/EP1007026A4/fr not_active Withdrawn
- 1998-01-13 CA CA002277273A patent/CA2277273C/fr not_active Expired - Fee Related
- 1998-01-13 JP JP53447398A patent/JP2001509176A/ja not_active Ceased
- 1998-01-13 AU AU60231/98A patent/AU729869B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
CA2277273A1 (fr) | 1998-07-23 |
WO1998031359A1 (fr) | 1998-07-23 |
AU729869B2 (en) | 2001-02-15 |
EP1007026A1 (fr) | 2000-06-14 |
AU6023198A (en) | 1998-08-07 |
EP1007026A4 (fr) | 2002-08-07 |
JP2001509176A (ja) | 2001-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2277273C (fr) | Antagonistes d'integrine | |
AU722360B2 (en) | Integrin antagonists | |
US6017925A (en) | Integrin antagonists | |
AU717283B2 (en) | Integrin antagonists | |
AU748621B2 (en) | Integrin receptor antagonists | |
AU747784B2 (en) | Integrin receptor antagonists | |
US5919792A (en) | Integrin antagonists | |
AU720758B2 (en) | Alphavbeta3 antagonists | |
US6413955B1 (en) | Integrin receptor antagonists | |
US5952341A (en) | Integrin antagonists | |
AU747503B2 (en) | Benzazepine derivatives as alpha-V integrin receptor antagonists | |
AU1912899A (en) | Integrin receptor antagonists | |
EP1194151A1 (fr) | Antagonistes des recepteurs de l'integrine | |
US5925655A (en) | αv β3 antagonists | |
US6211184B1 (en) | Integrin antagonists | |
US6294549B1 (en) | Method for eliciting an αvβ5 or dual αvβ3/αvβ5 antagonizing effect | |
US6916810B2 (en) | αν integrin receptor antagonists | |
CA2268916A1 (fr) | Antagonistes de l'integrine | |
Duggan et al. | α v β 3 antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |